Busy Day at the FDA

Yesterday the FDA announced not just one but two approvals in the diabetes device arena. Senseonics received approval for their Eversense implantable CGM while Tandem (NASDAQ: TNDM) received approval for their t:slim X2™ Insulin Pump with Basal-IQ™ technology. Of the two approvals we see the Tandem as more significant as it puts them on a path to compete head on with insulin pump market leader Medtronic (NYSE: MDT).

A few quick comments as many see this as the dawn of new era at the FDA and it may well be. After years of moving at glacial . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

This entry was posted in Email Alerts. Bookmark the permalink.